Biogen and Ionis’ spinal muscular atrophy treatment meets primary endpoint in phase 3 study
Biogen and Ionis Pharmaceuticals said that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint in a phase 3 trial.
